Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
1994 pubmed

Calmodulin-binding peptides interfere with melanocyte-stimulating hormone receptor activity and stimulate adenosine 3',5'-monophosphate production in M2R mouse melanoma cells.

Eshel. Y Y; Salomon. Y Y

Key Findings

  • Calmodulin‑binding peptides (CBPs) block MSH receptor binding and reduce adenylate cyclase activation in mouse melanoma cells.
  • When the natural hormone MSH is absent, the same CBPs actually increase cAMP production, acting as partial agonists.
  • CBPs work by inserting into cell membranes and interacting with lipid‑embedded parts of the signaling pathway, and this effect is calcium‑independent.

Practical Outcomes

  • The findings are purely mechanistic and don’t translate into any actionable advice for using melanotan‑I or related peptides in humans. Biohackers looking for dosing or performance benefits won’t gain practical guidance from this work.

Summary

This study looks at how certain lab‑made peptides that bind calmodulin can block the natural hormone receptor for melanin production in mouse melanoma cells and oddly boost a signaling molecule (cAMP) when the hormone isn’t present. It’s a detailed cell‑biology experiment and doesn’t test melanotan‑I or give any tips for human use.

Abstract

The MSH receptor belongs to a unique class of G-protein-coupled receptors, in which calcium ions control the binding affinity of MSH by a yet unknown mechanism. Possible involvement of a calcium-binding protein [e.g. calmodulin (CaM)] in the regulation of MSH receptor activity has been studied in the M2R mouse melanoma cell line. In this study, we tested the inhibitory effects of a group of calmodulin-binding peptides (CBPs) on MSH receptor activities in intact M2R cells and membrane preparations derived from them. We also report here on stimulatory effects of CBPs on cAMP production in M2R cells that could not be produced in other cell lines lacking MSH receptors. This group of CBPs includes synthetic peptides comprising the CaM-binding domains of Ca2+/CaM-dependent enzymes, cytotoxic venom peptides, and peptide hormones that have been reported to directly interact with CaM. The results show that CBPs, at micromolar concentrations, inhibit MSH binding and consequent adenylate cyclase stimulation in a specific and concentration-dependent manner, but have no effect on adenylate cyclase stimulation by prostaglandin E1. On the other hand, when MSH was omitted and forskolin (0.5-1 microM) was added instead, CBPs had the opposite effect on cAMP production, stimulating it in M2R cells, but not in other cell types tested. Thus, these peptides can be considered as antagonists of MSH receptor and partial agonists of M2R adenylate cyclase. In contrast to MSH, the stimulatory effects of CBPs were unaffected by EGTA, suggesting a Ca(2+)-independent action of these peptides. Using phospholipid vesicles and M2R cells, we recently showed that CBP activity in M2R cells may include direct partition into the lipid bilayer of the cell membrane, permitting interaction with hydrophobic lipid-inserted domains of components of the signal transducing machinery. Based on these findings, we suggest that the mechanism of action of CBPs in the M2R cells includes two major components: 1) interaction with the cell surface membrane and penetration into the lipid milieu, and 2) interaction with exposed or lipid-embedded protein epitopes intrinsically associated with the MSH-receptor system, thereby affecting the MSH receptor cascade.

Study Information

Provider

pubmed

Year

1994

DOI

10.1210/endo.134.1.8275931